

27. **Vickers AJ, Cronin AM, Bjork T, et al.** Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. *BMJ* 2010; 341: c4521.
28. **Carlsson S, Assel M, Sjoberg D, et al.** Influence of prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. *BMJ* 2014; 348: g2206.
29. **Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J.** Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer – results from a prospective, population-based randomized controlled trial. *Eur Urol* 2007; 51: 659–664.
30. **Hayes JH, Barry MJ.** Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. *JAMA* 2014; 311: 1143–1149.
31. **Draisma G, Etzioni R, Tsodikov A, et al.** Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. *J Natl Cancer Inst* 2009; 101: 374–383.
32. **Rosario DJ, Lane JA, Metcalfe C, et al.** Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT stud. *BMJ* 2012; 344: d7894.
33. **Chou R, Crosswell JM, Dana T, et al.** Screening for prostate cancer: a review of the evidence for the U.S. Preventive Task Force. *Ann Intern Md* 2011; 155: 762–771.
34. **Wilt TJ, Brawer MK, Jones KM.** Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012; 367: 582.
35. **Vickers AJ, Sjoberg DD, Ulmert D, et al.** Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. *BMC Med* 2014; 12: 26.
36. **Gulati R, Tsodikov A, Wever EM, et al.** The impact of PLCO control arm contamination on perceived PSA screening efficacy. *Cancer Causes Control* 2012; 23: 827–835.
37. <http://www.linkos.cz/prevence-a-skrining/onkoprevence-pro-ceskou-republiku-1/>.
38. www.mamo.cz.
39. www.kolorektum.cz.
40. www.cervix.cz.
41. <http://reporting.uzis.cz/>.
42. <https://www.uzis.cz/registry-nzis/nor>.

Do České urologie č. 2 / 2018 připravujeme

- Diagnostika karcinomu prostaty pomocí fúzní biopsie
- Monorova choroba penisu
- Porovnání detekce signifikantního a nesignifikantního karcinomu pomocí systematické a cílené fúzní MRI/TRUS biopsie prostaty
- Vliv denzity a velikosti litiázy na výsledek flexibilní ureterorenoskopie
- Primární Ewingův sarkom ledviny u mladé ženy